 DURHAM, N.C.BUSINESS WIREKBI Biopharma, Inc. KBI, a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. Mapp for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus SUDV. With the recent outbreak in Uganda, Mapp was contracted by the Biomedical Advanced Research ... KBI Biopharma Announces Subcontract with Mapp Biopharmaceuti... 